ATE522207T1 - Zusammensetzungen und nahrungsmittel zur verbesserung des fettstoffwechsels - Google Patents

Zusammensetzungen und nahrungsmittel zur verbesserung des fettstoffwechsels

Info

Publication number
ATE522207T1
ATE522207T1 AT03705174T AT03705174T ATE522207T1 AT E522207 T1 ATE522207 T1 AT E522207T1 AT 03705174 T AT03705174 T AT 03705174T AT 03705174 T AT03705174 T AT 03705174T AT E522207 T1 ATE522207 T1 AT E522207T1
Authority
AT
Austria
Prior art keywords
alkenyl
alkyl
hop extract
agents
foods
Prior art date
Application number
AT03705174T
Other languages
English (en)
Inventor
Hiroaki Yajima
Yutaka Miura
Daisuke Fujiwara
Hideharu Odai
Keiji Kondo
Hajime Nozawa
Original Assignee
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27736496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE522207(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin Brewery filed Critical Kirin Brewery
Application granted granted Critical
Publication of ATE522207T1 publication Critical patent/ATE522207T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3486—Humulus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
AT03705174T 2002-02-14 2003-02-14 Zusammensetzungen und nahrungsmittel zur verbesserung des fettstoffwechsels ATE522207T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002036798 2002-02-14
JP2002139700 2002-05-15
PCT/JP2003/001571 WO2003068205A1 (en) 2002-02-14 2003-02-14 Compositions and foods for improving lipid metabolism

Publications (1)

Publication Number Publication Date
ATE522207T1 true ATE522207T1 (de) 2011-09-15

Family

ID=27736496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03705174T ATE522207T1 (de) 2002-02-14 2003-02-14 Zusammensetzungen und nahrungsmittel zur verbesserung des fettstoffwechsels

Country Status (8)

Country Link
US (2) US20060233902A1 (de)
EP (1) EP1481671B9 (de)
JP (2) JPWO2003068205A1 (de)
KR (1) KR100993113B1 (de)
CN (1) CN1870983B (de)
AT (1) ATE522207T1 (de)
AU (1) AU2003211997B2 (de)
WO (1) WO2003068205A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US8142819B2 (en) 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US8206753B2 (en) 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US20040115290A1 (en) 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7901713B2 (en) 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US8168234B2 (en) 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
JP2006508182A (ja) * 2002-10-21 2006-03-09 メタプロテオミクス， エルエルシー 炎症応答と関連した病理学的状態を処置または抑制する組成物。
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US7144590B2 (en) * 2003-01-09 2006-12-05 Lipoprotein Technologies, Inc. Bioactive compositions derived from humulus lupulus
JP2005104951A (ja) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
JP4889954B2 (ja) * 2004-03-16 2012-03-07 株式会社 資生堂 女性ホルモン調節機能調整用香料組成物
US20070218155A1 (en) * 2004-08-20 2007-09-20 Kuhrts Eric H Methods and compositions for treating dyslipidaemia
JP4347161B2 (ja) * 2004-08-20 2009-10-21 キリンフードテック株式会社 ホップ抽出物含有組成物
EP2263663A1 (de) * 2004-11-13 2010-12-22 Metaproteomics, LLC Zusammensetzungen enthaltend Kurkuminoide und entweder alpha- oder beta-Säuren zur Behandlung von Diabetes
AU2006280074A1 (en) 2005-08-09 2007-02-22 Metaproteomics, Llc Protein kinase modulation by hops and acacia products
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2737897A3 (de) * 2005-12-09 2014-10-01 Metaproteomics, LLC Botanische entzündungshemmende Produkte zur Behandlung des metabolischen Syndroms und von Diabetes
NZ568860A (en) * 2005-12-09 2012-09-28 Metaproteomics Llc Protein kinase modulation by hops and acacia products
SG173310A1 (en) * 2006-03-23 2011-08-29 Emelita De Guzman Breyer Apolipoprotein fingerprinting technique
TW200816980A (en) * 2006-06-20 2008-04-16 Metaproteomics Llc Beta acid based protein kinase modulation cancer treatment
CA2679847A1 (en) * 2007-03-19 2008-09-25 Metaproteomics, Llc. Methods and compositions for promoting bone and joint health
WO2008140842A1 (en) 2007-05-11 2008-11-20 Metaproteomics, Llc Methods and compositions for heavy metal detoxification
JP5214632B2 (ja) * 2007-12-04 2013-06-19 サッポロビール株式会社 骨吸収抑制剤
JPWO2009072576A1 (ja) * 2007-12-04 2011-04-28 サッポロビール株式会社 骨形成促進剤
CA2708613A1 (en) * 2007-12-10 2009-06-18 Metaproteomics, Llc Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith
AU2010222848A1 (en) * 2009-03-09 2011-10-20 Surface Logix, Inc. Rho kinase inhibitors
WO2010143719A1 (ja) 2009-06-12 2010-12-16 キリンホールディングス株式会社 ホップエキスのアルカリ分解産物およびその用途
WO2011019999A1 (en) * 2009-08-14 2011-02-17 Metaproteomics, Llc Tetrahydro-isoalpha acid compositions and methods for weight management
ES2886057T3 (es) * 2010-05-21 2021-12-16 Coors Brewing Co Preparación de ácidos de lúpulo y sus derivados
WO2012058649A1 (en) * 2010-10-30 2012-05-03 Kindex Therapeutics, Llc Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(-3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods
US11179429B2 (en) 2010-12-15 2021-11-23 Kirin Holdings Kabushiki Kaisha Hop oxidation-reaction product, preparing method thereof and use thereof
NZ612722A (en) 2010-12-15 2015-11-27 Kirin Holdings Kk Hop extract oxidation-reaction product, preparing method thereof and use thereof
JP5946636B2 (ja) * 2011-12-15 2016-07-06 キリンホールディングス株式会社 イソフムロン類を含む自律神経調節剤
KR101523812B1 (ko) * 2012-03-07 2015-05-28 손원록 율초 추출물을 유효성분으로 함유하는 대사성 질환 예방 및 치료용 조성물
EP2865744B1 (de) * 2012-06-20 2024-07-31 Kirin Holdings Kabushiki Kaisha Getränk mit einem wässrigen medienextrakt aus in einer oxidation verwendetem hopfen
BR112014032127A2 (pt) * 2012-06-20 2017-06-27 Kirin Kk bebida efervescente que compreende um extrato de produtos de reação de oxidação de lúpulo
JP6340523B2 (ja) 2012-10-29 2018-06-13 国立大学法人京都大学 希少脂肪酸を含む代謝改善剤
JP6846416B2 (ja) 2016-05-13 2021-03-24 サントリーホールディングス株式会社 ホップ加工品
JP6121595B2 (ja) * 2016-05-25 2017-04-26 キリンホールディングス株式会社 イソフムロン類を含む自律神経調節剤
JP7103748B2 (ja) * 2016-10-05 2022-07-20 サッポロビール株式会社 Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物
US9968856B1 (en) 2016-11-15 2018-05-15 Genvid Technologies, Inc. Systems and methods of video game streaming with interactive overlay and additional data
CN110087492A (zh) * 2016-12-20 2019-08-02 三得利控股株式会社 含有异黄腐酚的脂质代谢促进用组合物
KR102197866B1 (ko) 2020-06-25 2021-01-04 박성율 일라이트 용출액을 함유하는 피지 분비 억제, 여드름 개선 또는 피부 진정 화장품 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898374A (en) * 1954-03-01 1959-08-04 Schwarz Lab Inc Nucleus alkylated phloracylophenones and procedure for the production of such compounds
FR1164537A (fr) 1956-05-24 1958-10-10 Mono Ets Produit alimentaire de régime
CH492780A (de) * 1966-01-05 1970-06-30 Brauerei Ind Ag F Verfahren zur Herstellung von Isohumulon enthaltenden Hopfenextrakten
GB1362695A (en) * 1970-09-17 1974-08-07 Carlton & United Breweries Isomerised hop extract
JPS589084B2 (ja) * 1973-10-29 1983-02-18 マツイ トクタロウ ホツプフンマツオヨビホツプエキスノ セイゾウホウホウ
JPS52145509A (en) * 1976-05-27 1977-12-03 Tokutarou Matsui Antitumor agent
GB1576729A (en) * 1976-10-13 1980-10-15 Brewing Patents Ltd Method of making an iso-acid preparation from hops
JPS5959623A (ja) * 1982-09-29 1984-04-05 Daigo Eiyou Kagaku Kk 抗糖尿病剤
DE3513169A1 (de) * 1985-04-12 1986-10-16 Hopstabil Hopfenverarbeitungs-Gesellschaft mbH, 8069 Wolnzach Verfahren zur herstellung von isohumulonen
US5013571A (en) * 1990-01-31 1991-05-07 Pfizer Inc. Methods for making tetrahydroisoalpha and hexahydroisoalpha acids
JP3155003B2 (ja) * 1990-11-06 2001-04-09 サントリー株式会社 ホップエキスの製造法および該方法により得られるホップエキス
JP2514860B2 (ja) * 1990-11-30 1996-07-10 アサヒビール株式会社 活性酸素消去のために使用するホップ抽出物とその利用
JP3313124B2 (ja) * 1991-07-31 2002-08-12 森下仁丹株式会社 親水性物質を内容物とするシームレスカプセルおよびその製法
WO1993024605A1 (en) 1992-06-04 1993-12-09 S.S. Steiner, Inc. Production of isomerized hop extract
US5286506A (en) * 1992-10-29 1994-02-15 Bio-Technical Resources Inhibition of food pathogens by hop acids
JPH06312924A (ja) * 1993-04-28 1994-11-08 Asahi Breweries Ltd 抗酸化作用を有するフムロン類の利用
JP3814309B2 (ja) * 1994-04-12 2006-08-30 リポプロテイン・テクノロジーズ・インコーポレイテッド 骨粗鬆症治療剤
EP0677289B1 (de) 1994-04-12 1999-01-13 Hoechst Marion Roussel, Ltd. Arzneimittel zur Behandlung von Osteoporose
JPH07285856A (ja) * 1994-04-21 1995-10-31 Hoechst Japan Ltd 骨粗鬆症治療剤
TW412425B (en) * 1994-10-18 2000-11-21 Kao Corp Dentifrice composition having capsule particles
AU8747498A (en) * 1997-08-22 1999-03-16 Nippon Shinyaku Co. Ltd. Food-preservative composition
ES2134743B1 (es) * 1998-02-06 2000-05-01 Biocosmetics Sl Composicion para el tratamiento de la halitosis.
JPH11335231A (ja) 1998-05-20 1999-12-07 Shiseido Co Ltd 痩身用皮膚外用剤
GB9824614D0 (en) * 1998-11-11 1999-01-06 Glaxo Group Ltd Chemical compounds
CN1269226A (zh) 1999-04-01 2000-10-11 陈江辉 一种无醇消脂减肥啤酒及其制备方法
DE60028368T2 (de) * 1999-04-15 2007-02-01 Kaneka Corp. Agonisten des peroxisom aktivator-responsiven rezeptors
US6734199B1 (en) * 1999-08-23 2004-05-11 Kyorin Pharmaceutical Co., Ltd. Substituted benzylthiazolidine-2, 4-dione derivatives
JP4678904B2 (ja) * 1999-11-02 2011-04-27 アサヒビール株式会社 ホップより得られる体重増加抑制物質
JP2001226274A (ja) * 2000-02-09 2001-08-21 Matsuura Yakugyo Kk リパーゼ阻害剤
JP2001261612A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬
JP4521703B2 (ja) * 2000-05-17 2010-08-11 アサヒビール株式会社 ホップより得られるリパーゼ阻害剤
JP5226912B2 (ja) 2000-06-12 2013-07-03 花王株式会社 Ｐｐａｒ活性化剤
KR20040054738A (ko) * 2001-10-26 2004-06-25 메타프로테오믹스, 엘엘씨 시클로옥시게나제-2의 발현 및/또는 활성의 상승 억제를나타내는 쿠르쿠미노이드 조성물
JP4247422B2 (ja) * 2002-02-01 2009-04-02 秋田県 アルドースリダクターゼ阻害作用剤

Also Published As

Publication number Publication date
JPWO2003068205A1 (ja) 2005-06-02
JP5295925B2 (ja) 2013-09-18
EP1481671B1 (de) 2011-08-31
WO2003068205A1 (en) 2003-08-21
AU2003211997A1 (en) 2003-09-04
KR100993113B1 (ko) 2010-11-08
CN1870983B (zh) 2010-12-01
EP1481671B9 (de) 2014-02-19
US20100080862A1 (en) 2010-04-01
EP1481671A1 (de) 2004-12-01
US20060233902A1 (en) 2006-10-19
AU2003211997B2 (en) 2009-01-29
JP2010018631A (ja) 2010-01-28
KR20040084908A (ko) 2004-10-06
CN1870983A (zh) 2006-11-29
EP1481671A4 (de) 2007-09-19

Similar Documents

Publication Publication Date Title
ATE522207T1 (de) Zusammensetzungen und nahrungsmittel zur verbesserung des fettstoffwechsels
AU674394B2 (en) Methods for inhibiting bone loss with 3,4-diarylchroman
JB et al. The effects of phytoestrogens on bone
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
Elad et al. Oral graft-versus-host disease: a pictorial review and a guide for dental practitioners
CN1400904A (zh) 与雌激素联合的选择性雌激素受体调节剂
MXPA02011632A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004779A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
NZ505453A (en) Hypolipidemic benzothiazepine compounds
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AU3563695A (en) Novel piperidine derivatives with paf antagonist activity
JP3873097B2 (ja) 抗肥満剤及び脂質代謝改善剤
MX9706647A (es) Composiciones farmaceuticas que comprenden inhibidores de oxidasa b de monoamina.
KR970702291A (ko) 에퀼린의 산 이성질화체로부터 제조된 에퀼린 이중결합 이성질체(Anequilin double bond isomer from the acid isomerization of equilin)
GR3022615T3 (en) Pharmaceutical compositions based on ebastime or analogues thereof.
US20040116498A1 (en) Regulations of lipids and/or bone density and compositions therefor
HUT75942A (en) Neuroprotective chroman compounds and pharmaceutical compositions containing them
EP1652533A4 (de) Herzverlangsamender arzneistoff mit beta-blockern mit kurzzeitwirkung als wirkstoff
Furuta Cadmium effects on bone and dental tissues of rats in acute and subacute poisoning
Muradin et al. A prospective study on the effect of modified alar cinch sutures and VY closure versus simple closing sutures on nasolabial changes after Le Fort I intrusion and advancement osteotomies
Irving et al. The selective action of papain on calcification sites
Innes et al. Multiple myelomatosis treated with a combination of urethane and an oral nitrogen mustard
HUP0003463A2 (hu) Piperidinil-metil-oxazolidinon-származék, eljárás ennek előállítására és a vegyületet tartalmazó gyógyszerkészítmény
Jee et al. Extra cancellous bone induced by combined prostaglandin E2 and risedronate administration is maintained after their withdrawal in older female rats

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties